{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:03:58Z","timestamp":1781528638003,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["HMSP-ICS\/0004\/2011, Career Development Award"],"award-info":[{"award-number":["HMSP-ICS\/0004\/2011, Career Development Award"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dana-Farber Cancer Institute Friends Grant","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Dana-Farber Cancer Institute Friends Grant","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s10549-016-3927-4","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T06:55:37Z","timestamp":1470120937000},"page":"151-162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab"],"prefix":"10.1007","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-2260","authenticated-orcid":false,"given":"Ines","family":"Vaz-Luis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Lii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold J.","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"3927_CR1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747\u2013752","journal-title":"Nature"},{"key":"3927_CR2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"key":"3927_CR3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244:707\u2013712","journal-title":"Science"},{"key":"3927_CR4","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"3927_CR5","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"3927_CR6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273\u20131283","journal-title":"N Engl J Med"},{"key":"3927_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006243.pub2","author":"L Moja","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi S et al (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. doi: 10.1002\/14651858.CD006243.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"3927_CR8","unstructured":"National Comphreensive Cancer Network (NCCN) guidelines, Breast Cancer, Version 2.2016 (2016) http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf . Accessed 27 July 2016"},{"key":"3927_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. doi: 10.1093\/jnci\/dju055","journal-title":"J Natl Cancer Inst"},{"key":"3927_CR10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/cncr.27831","volume":"119","author":"RA Freedman","year":"2013","unstructured":"Freedman RA, Hughes ME, Ottesen RA et al (2013) Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race\/ethnicity and education within the National Comprehensive Cancer Network. Cancer 119:839\u2013846","journal-title":"Cancer"},{"key":"3927_CR11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1200\/JOP.2015.004747","volume":"12","author":"SD Byfield","year":"2016","unstructured":"Byfield SD, Buck PO, Blauer-Peterson C et al (2016) ReCAP: treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the United States: a real-world retrospective study. J Oncol Pract 12:159\u2013160","journal-title":"J Oncol Pract"},{"key":"3927_CR12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10549-014-2968-9","volume":"145","author":"RA Freedman","year":"2014","unstructured":"Freedman RA, Vaz-Luis I, Barry WT et al (2014) Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat 145:491\u2013501","journal-title":"Breast Cancer Res Treat"},{"key":"3927_CR13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2013.51.1261","volume":"32","author":"I Vaz-Luis","year":"2014","unstructured":"Vaz-Luis I, Keating NL, Lin NU et al (2014) Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 32:927\u2013934","journal-title":"J Clin Oncol"},{"key":"3927_CR14","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1200\/JCO.2015.65.8716","volume":"34","author":"K Reeder-Hayes","year":"2016","unstructured":"Reeder-Hayes K, Peacock Hinton S, Meng K et al (2016) Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer. J Clin Oncol 34:2003\u20132009","journal-title":"J Clin Oncol"},{"key":"3927_CR15","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1200\/JCO.2013.53.1608","volume":"32","author":"I Vaz-Luis","year":"2014","unstructured":"Vaz-Luis I, Ottesen RA, Hughes ME et al (2014) Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 32:2142\u20132150","journal-title":"J Clin Oncol"},{"key":"3927_CR16","first-page":"IV62","volume":"40","author":"AL Potosky","year":"2002","unstructured":"Potosky AL, Warren JL, Riedel ER et al (2002) Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 40:IV62\u2013IV68","journal-title":"Med Care"},{"key":"3927_CR17","first-page":"IV3","volume":"40","author":"JL Warren","year":"2002","unstructured":"Warren JL, Klabunde CN, Schrag D et al (2002) Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:IV3\u2013IV18","journal-title":"Med Care"},{"key":"3927_CR18","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.293.9.1073","volume":"293","author":"HB Muss","year":"2005","unstructured":"Muss HB, Woolf S, Berry D et al (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073\u20131081","journal-title":"JAMA"},{"key":"3927_CR19","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2005.02.3028","volume":"24","author":"SH Giordano","year":"2006","unstructured":"Giordano SH, Duan Z, Kuo YF et al (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24:2750\u20132756","journal-title":"J Clin Oncol"},{"key":"3927_CR20","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2006.10.2749","volume":"25","author":"JJ Griggs","year":"2007","unstructured":"Griggs JJ, Culakova E, Sorbero ME et al (2007) Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 25:2522\u20132527","journal-title":"J Clin Oncol"},{"key":"3927_CR21","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"EH Romond","year":"2012","unstructured":"Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792\u20133799","journal-title":"J Clin Oncol"},{"key":"3927_CR22","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","volume":"32","author":"E Azambuja de","year":"2014","unstructured":"de Azambuja E, Procter MJ, van Veldhuisen DJ et al (2014) Trastuzumab-associated cardiac events at 8\u00a0years of median follow-up in the herceptin adjuvant trial (BIG 1-01). J Clin Oncol 32:2159\u20132165","journal-title":"J Clin Oncol"},{"key":"3927_CR23","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","volume":"60","author":"J Chen","year":"2012","unstructured":"Chen J, Long JB, Hurria A et al (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504\u20132512","journal-title":"J Am Coll Cardiol"},{"key":"3927_CR24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","volume":"104","author":"EJ Bowles","year":"2012","unstructured":"Bowles EJ, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293\u20131305","journal-title":"J Natl Cancer Inst"},{"key":"3927_CR25","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","volume":"31","author":"M Chavez-MacGregor","year":"2013","unstructured":"Chavez-MacGregor M, Zhang N, Buchholz TA et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222\u20134228","journal-title":"J Clin Oncol"},{"key":"3927_CR26","doi-asserted-by":"crossref","unstructured":"Pituskin EN, Mackey JR, Koshman S et al (2015) Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpressing breast cancer patients receiving trastuzumab: primary results of the MANTICORE randomized controlled trial. In: San Antonio breast cancer symposium. San Antonio (abstr S1\u201305)","DOI":"10.1158\/1538-7445.SABCS15-S1-05"},{"key":"3927_CR27","doi-asserted-by":"crossref","unstructured":"Gulati G, Heck SL, Hoffmann PS (2015) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): primary results of a randomized, 2\u00a0\u00d7\u00a02 factorial, placebo-controlled, double-blind clinical trial. In: 2015 American Heart Association Scientific Sessions. Orlando (abstr 478895)","DOI":"10.1093\/eurheartj\/ehw022"},{"key":"3927_CR28","unstructured":"Florida UoS. Lisinopril or Coreg CR in reducing side effects in women with breast cancer receiving trastuzumab. 2009 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01009918 . Accessed 27 July 2016"},{"key":"3927_CR29","doi-asserted-by":"crossref","unstructured":"Vaz Duarte Luis I, Lin NU, Keating N et al\u00a0 (2015) Factors associated with early mortality in metastatic breast cancer (MBC) in a population based cohort. ASCO MEETING ABSTRACTS:1577. In: American Society of Clinical Oncology meeting 2015, Chicago","DOI":"10.1200\/jco.2015.33.15_suppl.1577"},{"key":"3927_CR30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.2008.17.9234","volume":"27","author":"RA Freedman","year":"2009","unstructured":"Freedman RA, He Y, Winer EP, Keating NL (2009) Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol 27:713\u2013719","journal-title":"J Clin Oncol"},{"key":"3927_CR31","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cncr.23228","volume":"112","author":"CP Gross","year":"2008","unstructured":"Gross CP, Smith BD, Wolf E, Andersen M (2008) Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer 112:900\u2013908","journal-title":"Cancer"},{"key":"3927_CR32","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1200\/JCO.2005.04.5799","volume":"24","author":"NA Bickell","year":"2006","unstructured":"Bickell NA, Wang JJ, Oluwole S et al (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24:1357\u20131362","journal-title":"J Clin Oncol"},{"key":"3927_CR33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10549-015-3432-1","volume":"151","author":"I Vaz-Luis","year":"2015","unstructured":"Vaz-Luis I, Lin NU, Keating NL et al (2015) Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat 151:697\u2013707","journal-title":"Breast Cancer Res Treat"},{"key":"3927_CR34","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1097\/MLR.0b013e31823ab60f","volume":"51","author":"JL Lund","year":"2013","unstructured":"Lund JL, Sturmer T, Harlan LC et al (2013) Identifying specific chemotherapeutic agents in medicare data: a validation study. Med Care 51:e27\u2013e34","journal-title":"Med Care"},{"key":"3927_CR35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372:134\u2013141","journal-title":"N Engl J Med"},{"key":"3927_CR36","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","volume":"53","author":"CN Klabunde","year":"2000","unstructured":"Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258\u20131267","journal-title":"J Clin Epidemiol"},{"key":"3927_CR37","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245\u20131251","journal-title":"J Clin Epidemiol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3927-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-016-3927-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3927-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T17:19:57Z","timestamp":1600967997000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-016-3927-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["3927"],"URL":"https:\/\/doi.org\/10.1007\/s10549-016-3927-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}